Innsbruck- Start of the 1st Austrian trial site

 On 11 June  2026, the Medical University of Innsbruck became officially the first active trial site of the STOP-PKD Study in Austria.

Dr. Michael Rudnicki´s team cares for patients with a wide range of nephrological issues, including those affected by autosomal dominant polycystic kidney disease (ADPKD).

Interested patients can now make an appointment at the trial site in Innsbruck to obtain detailed information about the trial and potential participation.

Phone:  +43 (0) 50504 25855

Email:  michael.rudnicki@i-med.ac.at